Sugi Predict

Sugi Predict / Compounds / SCHEMBL1377052

SCHEMBL1377052

SCHEMBL1377052

O=C(O)CCC(CS(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CPA3 P15088 1/20 0.56
▸ MMP9 P14780 3/20 0.53
▸ MMP8 P22894 3/20 0.53
▸ MMP2 P08253 2/20 0.53
▸ MMP1 P03956 1/20 0.53
▸ MMP3 P08254 1/20 0.53
▸ MMP13 P45452 1/20 0.46
▸ ADAMTS4 O75173 1/20 0.46
▸ ALDH1A1 P00352 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2D6 P10635 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ FOLH1 Q04609 3/20 0.44
▸ HSD11B1 P28845 2/20 0.44
▸ HDAC3 O15379 1/20 0.42
▸ HDAC4 P56524 1/20 0.42
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1374875 0.86 MMP1 (0.44) CPA3MMP9MMP8MMP2MMP1
SCHEMBL17697191 0.86 MMP2 (0.54) MMP9MMP8MMP2MMP1MMP3
SCHEMBL7988020 0.83 MMP1 (0.53) MMP9MMP8MMP2MMP1MMP3
SCHEMBL7075141 0.80 MMP2 (0.80) MMP9MMP8MMP2MMP1MMP3
SCHEMBL7327841 0.78 CYP1A2 (0.63) CPA3MMP9MMP8MMP2MMP1
SCHEMBL7349315 0.78 CYP1A2 (0.63) CPA3MMP9MMP8MMP2MMP1
SCHEMBL8909236 0.78 CYP1A2 (0.63) CPA3MMP9MMP8MMP2MMP1
SCHEMBL1373606 0.78 CPA3 (0.66) CPA3CYP1A2FOLH1
SCHEMBL3774843 0.76 CPA3 (0.51) CPA3MMP9MMP8MMP13ADAMTS4
SCHEMBL5412108 0.75 HSD11B1 (0.53) MMP9MMP8MMP2MMP1MMP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6395718-B1 RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS GUILFORD PHARMACEUTICALS INC. 2002-05-28 — — US claimed
JP-2001521512-A — — 2001-11-06 — — JP claimed
EP-1019369-A1 THIO DERIVATIVES AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2000-07-19 — — EP claimed
US-5977090-A Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 1999-11-02 — — US claimed
WO-1998045257-A1 THIO DERIVATIVES AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-10-15 — — WO claimed
US-20260007756-A1 COMPOUND AND USE THEREOF COHERENT BIOPHARMA SUZHOU LTD (CN) 2026-01-08 — — US disclosed
US-12496292-B2 PSMA binding ligand-linker conjugates and methods for using PURDUE RESEARCH FOUNDATION (US) 2025-12-16 — — US disclosed
US-20250127939-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY PURDUE RESEARCH FOUNDATION 2025-04-24 — — US disclosed
EP-4541378-A2 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY Endocyte, Inc. (US) 2025-04-23 — — EP disclosed
US-20250108039-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING PURDUE RESEARCH FOUNDATION 2025-04-03 — — US disclosed
EP-4512426-A1 COMPOUND AND USE THEREOF Coherent Biopharma (Suzhou), Limited (CN) 2025-02-26 — — EP disclosed
EP-3777898-B1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY ENDOCYTE INC (US) 2025-01-01 — — EP disclosed
WO-2003035688-A2 TARGETED THROMBOSIS BY TISSUE FACTOR POLYPEPTIDES NOVARTIS PHARMA GMBH (AT) 2003-05-01 — — WO disclosed
US-20030064912-A1 Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors SLUSHER BARBARA S (US) 2003-04-03 — — US disclosed
US-6395718-B1 RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; CARDIOVASCULAR DISORDERS GUILFORD PHARMACEUTICALS INC. 2002-05-28 — — US disclosed
EP-1019369-A1 THIO DERIVATIVES AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 2000-07-19 — — EP disclosed
US-5977090-A Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 1999-11-02 — — US disclosed
EP-0949922-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-10-20 — — EP disclosed
WO-1998045257-A1 THIO DERIVATIVES AS NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-10-15 — — WO disclosed
WO-1998013044-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250108039-A1 PSMA BINDING LIGAND-LINKER CONJUGATES AND METHODS FOR USING FOLH1, KLK3, PSMA1 CPA3 525/4885MMP9 2571/4885MMP8 3252/4885
US-12496292-B2 PSMA binding ligand-linker conjugates and methods for using FOLH1, KLK3, PSMA1 CPA3 525/4885MMP9 2571/4885MMP8 3252/4885
US-20030064912-A1 Pharmaceutical compositions and methods of inhibiting angiogenesis using NAALADase inhibitors NAALAD2, DNPEP, DPP9 CPA3 193/4885MMP9 55/4885MMP8 59/4885
US-20250127939-A1 COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY VHL, PC, NPC1 CPA3 1830/4885MMP9 2926/4885MMP8 1302/4885
US-20260007756-A1 COMPOUND AND USE THEREOF FOLH1, TRPV6, FOLR1 CPA3 217/4885MMP9 880/4885MMP8 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.